Deciphera Pharmaceuticals/DCPH

$14.90

-0.99%
-
1D1W1MYTD1YMAX

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Ticker

DCPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Steven Hoerter

Employees

355

Headquarters

Waltham, United States

DCPH Metrics

BasicAdvanced
$1.22B
Market cap
-
P/E ratio
-$2.29
EPS
0.40
Beta
-
Dividend rate
$1.22B
0.3973
$17.73
$9.90
536.81K
3.801
3.589
-42.03%
-56.29%
-52.63%
7.444
3.453
3.465
21.87%
10%
57.16%

What the Analysts think about DCPH

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
62.42% upside
High $34.00
Low $9.00
$14.90
Current price
$24.20
Average price target

DCPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-97.71% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$48.2M
11.32%
Net income
$-47.1M
-4.85%
Profit margin
-97.71%
-14.52%

DCPH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.97%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.60
-$0.57
-$0.58
-$0.54
-
Expected
-$0.59
-$0.62
-$0.61
-$0.58
-$0.55
Surprise
1.15%
-8.06%
-4.73%
-6.97%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Deciphera Pharmaceuticals stock?

Deciphera Pharmaceuticals (DCPH) has a market cap of $1.22B as of April 16, 2024.

What is the P/E ratio for Deciphera Pharmaceuticals stock?

The price to earnings (P/E) ratio for Deciphera Pharmaceuticals (DCPH) stock is 0 as of April 16, 2024.

Does Deciphera Pharmaceuticals stock pay dividends?

No, Deciphera Pharmaceuticals (DCPH) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Deciphera Pharmaceuticals dividend payment date?

Deciphera Pharmaceuticals (DCPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals (DCPH) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Deciphera Pharmaceuticals stock price target?

The target price for Deciphera Pharmaceuticals (DCPH) stock is $24.2, which is 62.42% above the current price of $14.9. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Deciphera Pharmaceuticals stock

Buy or sell Deciphera Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing